Lead Essay: Money, Equity and Access to Medicines.
作者信息
Ghinea Narcyz, Lipworth Wendy, Kerridge Ian
机构信息
Sydney Health Ethics, University of Sydney, Level 1, Medical Foundation Building K25, Sydney, NSW, 2006, Australia.
出版信息
J Bioeth Inq. 2020 Mar;17(1):25-27. doi: 10.1007/s11673-020-09966-x.
PMID:32124176
Abstract
摘要
相似文献
1
Lead Essay: Money, Equity and Access to Medicines.
J Bioeth Inq. 2020 Mar;17(1):25-27. doi: 10.1007/s11673-020-09966-x.
2
From promises to policies: is big pharma delivering on transparency?从承诺到政策：大型制药公司是否兑现了透明度承诺？
BMJ. 2014 Feb 26;348:g1615. doi: 10.1136/bmj.g1615.
3
The global impact of Indian generics on access to health.印度仿制药对医疗可及性的全球影响。
Indian J Med Ethics. 2013 Apr-Jun;10(2):118-20. doi: 10.20529/IJME.2013.035.
4
Access to AIDS medicine: ethical considerations.
Indian J Med Ethics. 2004 Jul-Sep;1(3):75-6. doi: 10.20529/IJME.2004.039.
5
Can affordability and innovation coexist for medicines?药品的可负担性与创新性能否共存？
BMJ. 2020 Jan 13;368:l7058. doi: 10.1136/bmj.l7058.
6
Access to medication and drug company sales practices: setting priorities for critique and advocacy.
Am J Bioeth. 2003 Summer;3(3):61. doi: 10.1162/15265160360706642.
7
Getting the attention of Big Pharma. And Big Pharma is listening.
Hosp Health Netw. 2003 Oct;77(10):44-8, 2.
8
[The long path (s) of placing medicines on the market].[药品上市的漫长过程]
Med Sci (Paris). 2019 Mar;35 Hors série n° 1:13-17. doi: 10.1051/medsci/2019047. Epub 2019 Apr 3.
9
Accounting for US public funding in drug development: how can we better balance access, affordability, and innovation?解读美国药物研发中的公共资金投入：我们如何能更好地平衡可及性、可负担性与创新？
BMJ. 2020 Oct 8;371:m3841. doi: 10.1136/bmj.m3841.
10
Your money or your life: a new variation on the Heinz Dilemma.要钱还是要命：海因茨困境的新变体。
Physician Exec. 2004 Jan-Feb;30(1):58-61.
引用本文的文献
1
A novel Shiga toxin 2a neutralizing antibody therapeutic with low immunogenicity and high efficacy.一种新型的具有低免疫原性和高效力的志贺毒素 2a 中和抗体治疗药物。
Antimicrob Agents Chemother. 2024 Jan 10;68(1):e0059823. doi: 10.1128/aac.00598-23. Epub 2023 Dec 4.
Zotero 插件